Developer docs
API playgroundTry for free, no card

Search company profiles

AllazoHealth

Full company profile

uuid0007diy

Namestring
AllazoHealth
Company typeenum
Private
Founded yearint
2012
Descriptiontext

AllazoHealth is a New York-based, for-profit private company founded in 2012 that provides analytics services designed to improve medication adherence through individualized intervention targeting. The company operates in the healthcare/pharmaceutical software space, with its core product positioned as a patient-level analytics layer that selects the right adherence intervention for the right patient — a category commonly used by pharmaceutical manufacturers, payers, pharmacy benefit managers, and provider organizations seeking to lift script persistence, refill adherence, and outcomes-based contract performance. The firm's go-to-market is implicitly B2B, given its focus on adherence analytics and the company type, though the input does not disclose pricing, contract structure, named customers, or revenue model. The headcount band of 11-50 employees is consistent with a small analytics team rather than a scaled software platform, and the disclosed capital base is minimal — only $20,000 in funding is quantified (Blueprint Health, 2012), with subsequent rounds through 2016 from entities including the New York Digital Health Accelerator (2014) and the Harvard Business School Alumni Angels of Greater NY (2016).

The executive team is compact and function-complete for an early-stage healthcare analytics business: CEO William Grambley, founder/CTO Clifford Jones, CFO Francis Barker, and Chief Customer and Clinical Officer Linda Schultz. This composition implies an intent to bridge technical analytics, finance, and clinical/customer evidence — a structure typical of companies preparing for payer or pharma enterprise procurement, where clinical validation and customer success are gating requirements.

It is important to note that a large portion of the technology, product, and customer-segment detail provided in the input aggregation appears to be sourced from AssistRx's website rather than from AllazoHealth directly; the AssistRx profile (specialty pharmaceutical solutions platform with iAssist, CoAssist, Advanced eServices, and proprietary AI targeting/next-best-action capabilities) is a separate company, and AllazoHealth's own technology stack, product surface, and customer list are not independently disclosed in the available sources. As a result, the analytic picture for AllazoHealth is limited to firmographic, leadership, and funding signals, with no verifiable product, technology, or commercial detail beyond the adherence-analytics positioning.

Short descriptiontext

AllazoHealth is a New York-based healthcare analytics company, founded in 2012, that provides individualized intervention targeting to improve medication adherence for pharmaceutical and healthcare clients. It operates as a small private firm (11-50 employees) with minimal disclosed funding.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
medication adherence analytics, patient intervention targeting, healthcare AI platform, adherence prediction software, pharmaceutical analytics services
Industry2 codes
PRIMARYHLALAIAG
Medication Adherence & Therapy Management Platforms (refills, reminders, MTM)
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
SECONDARYHLACAKAF
Medication Adherence, Reminders & Patient Support
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
NAICS code1 code
  • Other Ambulatory Health Care Services6219
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Healthcare Analytics Software
Social media profiles2 records
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

AllazoHealth provides analytics services that improve medication adherence through individualized intervention targeting. Leveraging AI, the platform identifies patients at risk of non-adherence and recommends tailored interventions and engagement strategies designed to improve therapy uptake and persistence for healthcare and life sciences organizations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • M+ transactions processed annually
+2 more records
Product and service1 record
1Medication Adherence Analytics Platform
CategoryHealthcare Analytics Software
Description

AllazoHealth's AI-driven analytics platform improves medication adherence by identifying patients at risk of non-adherence and recommending individualized intervention strategies. It is sold to pharmaceutical manufacturers, payers, and healthcare providers to scale targeted adherence support.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

RxAnte is a medication adherence analytics platform owned by McKesson that uses predictive models to help health plans target interventions for Medicare Star Ratings and adherence measures — a direct competitor in adherence analytics.

TypeEmerging player
Description

AiCure applies AI to patient behavior monitoring and adherence in clinical trials and commercial therapies; comparable as an AI-driven adherence and patient engagement company serving pharma.

TypeBroad incumbent
Description

OptumRx is one of the largest PBMs in the U.S. and runs internal adherence programs and analytics for its payer clients; a broad incumbent that could build or acquire competing adherence-targeting capabilities.

TypeDirect peer
Description

AdhereHealth provides medication adherence analytics and outreach services to health plans and PBMs, using predictive analytics to prioritize interventions — directly comparable to AllazoHealth's adherence-targeting analytics model.

TypeBroad incumbent
Description

Surescripts operates the dominant U.S. e-prescribing network and increasingly offers medication intelligence and adherence-related data services to payers and providers — a broad incumbent in prescription data infrastructure.

6AdhereTech
TypeEmerging player
Description

AdhereTech combines smart connected pill bottles with adherence analytics for pharma and clinical trial clients — a partial-overlap adherence platform with a different primary data-collection modality.

TypeEmerging player
Description

Medisafe is a digital medication management platform using personalized reminders and AI to improve adherence; overlapping use cases with AllazoHealth though typically more patient-facing than payer-facing.

TypeEmerging player
Description

HealthPrize provides gamified patient engagement and adherence solutions for pharma brands; adjacent to AllazoHealth's adherence-improvement offering but more rewards/engagement-led than predictive-analytics-led.

TypeBroad incumbent
Description

Health Dialog, part of Rite Aid / Healthmap Solutions, offers adherence and chronic condition management programs for health plans; broader healthcare engagement portfolio but overlapping adherence analytics and outreach value proposition.

TypeBroad incumbent
Description

Mercalis provides patient access, affordability, and adherence solutions for specialty pharma manufacturers at scale; broader portfolio than AllazoHealth but overlapping adherence/patient support value proposition.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AllazoHealth

Healthcare Analytics Softwareallazohealth.com

AllazoHealth is a New York-based healthcare analytics company, founded in 2012, that provides individualized intervention targeting to improve medication adherence for pharmaceutical and healthcare clients. It operates as a small private firm (11-50 employees) with minimal disclosed funding.

What AllazoHealth does

AllazoHealth is a New York-based, for-profit private company founded in 2012 that provides analytics services designed to improve medication adherence through individualized intervention targeting. The company operates in the healthcare/pharmaceutical software space, with its core product positioned as a patient-level analytics layer that selects the right adherence intervention for the right patient — a category commonly used by pharmaceutical manufacturers, payers, pharmacy benefit managers, and provider organizations seeking to lift script persistence, refill adherence, and outcomes-based contract performance. The firm's go-to-market is implicitly B2B, given its focus on adherence analytics and the company type, though the input does not disclose pricing, contract structure, named customers, or revenue model. The headcount band of 11-50 employees is consistent with a small analytics team rather than a scaled software platform, and the disclosed capital base is minimal — only $20,000 in funding is quantified (Blueprint Health, 2012), with subsequent rounds through 2016 from entities including the New York Digital Health Accelerator (2014) and the Harvard Business School Alumni Angels of Greater NY (2016).

The executive team is compact and function-complete for an early-stage healthcare analytics business: CEO William Grambley, founder/CTO Clifford Jones, CFO Francis Barker, and Chief Customer and Clinical Officer Linda Schultz. This composition implies an intent to bridge technical analytics, finance, and clinical/customer evidence — a structure typical of companies preparing for payer or pharma enterprise procurement, where clinical validation and customer success are gating requirements.

It is important to note that a large portion of the technology, product, and customer-segment detail provided in the input aggregation appears to be sourced from AssistRx's website rather than from AllazoHealth directly; the AssistRx profile (specialty pharmaceutical solutions platform with iAssist, CoAssist, Advanced eServices, and proprietary AI targeting/next-best-action capabilities) is a separate company, and AllazoHealth's own technology stack, product surface, and customer list are not independently disclosed in the available sources. As a result, the analytic picture for AllazoHealth is limited to firmographic, leadership, and funding signals, with no verifiable product, technology, or commercial detail beyond the adherence-analytics positioning.

AllazoHealth firmographics

Firmographics
Name
AllazoHealth
Website
https://allazohealth.com
Company type
Private
Founded year
2012
Headcount range
1–10 employees
Short description
AllazoHealth is a New York-based healthcare analytics company, founded in 2012, that provides individualized intervention targeting to improve medication adherence for pharmaceutical and healthcare clients. It operates as a small private firm (11-50 employees) with minimal disclosed funding.
Ownership category
akta.pro rank

AllazoHealth industry classification

Industry
Product category
Healthcare Analytics Software
NAICS
Other Ambulatory Health Care Services (6219)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLALAIAG
Medication Adherence & Therapy Management Platforms (refills, reminders, MTM)
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
SECONDARYHLACAKAF
Medication Adherence, Reminders & Patient Support
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT

Keywords

  • Medication adherence analytics
  • Patient intervention targeting
  • Healthcare AI platform
  • Adherence prediction software
  • Pharmaceutical analytics services

Where AllazoHealth is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

AllazoHealth business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Distribution channels2 records

Marketing channels6 records

AllazoHealth product offering

Product offering

Core offering

AllazoHealth provides analytics services that improve medication adherence through individualized intervention targeting. Leveraging AI, the platform identifies patients at risk of non-adherence and recommends tailored interventions and engagement strategies designed to improve therapy uptake and persistence for healthcare and life sciences organizations.

Differentiator

Problem solved

Functional benefit

Products and services

  • Medication Adherence Analytics Platform AllazoHealth's AI-driven analytics platform improves medication adherence by identifying patients at risk of non-adherence and recommending individualized intervention strategies. It is sold to pharmaceutical manufacturers, payers, and healthcare providers to scale targeted adherence support.

Quantifiable outcome

  • M+ transactions processed annually
  • +2 more outcomes

Companies that use AllazoHealth

Customer profile

Segments2 records

Ideal customer profiles2 records

AllazoHealth technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

AllazoHealth partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves5 records

Expansion highlights3 records

AllazoHealth competitors and assessment

Company assessment

Direct peers

  • RxAnte: RxAnte is a medication adherence analytics platform owned by McKesson that uses predictive models to help health plans target interventions for Medicare Star Ratings and adherence measures — a direct competitor in adherence analytics.
  • AdhereHealth: AdhereHealth provides medication adherence analytics and outreach services to health plans and PBMs, using predictive analytics to prioritize interventions — directly comparable to AllazoHealth's adherence-targeting analytics model.

Emerging players

  • AiCure: AiCure applies AI to patient behavior monitoring and adherence in clinical trials and commercial therapies; comparable as an AI-driven adherence and patient engagement company serving pharma.
  • AdhereTech: AdhereTech combines smart connected pill bottles with adherence analytics for pharma and clinical trial clients — a partial-overlap adherence platform with a different primary data-collection modality.
  • Medisafe: Medisafe is a digital medication management platform using personalized reminders and AI to improve adherence; overlapping use cases with AllazoHealth though typically more patient-facing than payer-facing.
  • HealthPrize Technologies: HealthPrize provides gamified patient engagement and adherence solutions for pharma brands; adjacent to AllazoHealth's adherence-improvement offering but more rewards/engagement-led than predictive-analytics-led.

Broad incumbents

  • OptumRx (UnitedHealth Group): OptumRx is one of the largest PBMs in the U.S. and runs internal adherence programs and analytics for its payer clients; a broad incumbent that could build or acquire competing adherence-targeting capabilities.
  • Surescripts: Surescripts operates the dominant U.S. e-prescribing network and increasingly offers medication intelligence and adherence-related data services to payers and providers — a broad incumbent in prescription data infrastructure.
  • Health Dialog: Health Dialog, part of Rite Aid / Healthmap Solutions, offers adherence and chronic condition management programs for health plans; broader healthcare engagement portfolio but overlapping adherence analytics and outreach value proposition.
  • TrialCard (now Mercalis): Mercalis provides patient access, affordability, and adherence solutions for specialty pharma manufacturers at scale; broader portfolio than AllazoHealth but overlapping adherence/patient support value proposition.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

AllazoHealth social profiles

Digital presence

AllazoHealth financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AllazoHealth leadership team

Management profile

Number of profiles

Profiles4 records

AllazoHealth funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AllazoHealth M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AllazoHealth

What does AllazoHealth do?

AllazoHealth provides analytics services that improve medication adherence through individualized intervention targeting. Leveraging AI, the platform identifies patients at risk of non-adherence and recommends tailored interventions and engagement strategies designed to improve therapy uptake and persistence for healthcare and life sciences organizations.

When was AllazoHealth founded?

AllazoHealth was founded in 2012. It employs 1 to 10 people.

Where is AllazoHealth based?

AllazoHealth is headquartered in New York, United States, in the North America region.

Who are AllazoHealth's main competitors?

Direct peers on record are RxAnte and AdhereHealth. Emerging players are AiCure, AdhereTech, Medisafe and HealthPrize Technologies. Broad incumbents are OptumRx (UnitedHealth Group), Surescripts, Health Dialog and TrialCard (now Mercalis).

Does AllazoHealth have an API?

No public API is recorded for AllazoHealth.

What industry is AllazoHealth in?

AllazoHealth's product category is Healthcare Analytics Software. Its primary akta.pro industry code is HLALAIAG, Medication Adherence & Therapy Management Platforms (refills, reminders, MTM), with a secondary code of HLACAKAF, Medication Adherence, Reminders & Patient Support. Its NAICS code is 6219 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
P&S IntelligencePatient Engagement Solutions Market Size, and Growth Report, 2032P&S Intelligence released a market report forecasting the global patient engagement solutions market to grow from USD 20.3 billion in 2024 to USD 45.0 billion by 2032, driven by chronic disease prevalence and rising healthcare costs. The report highlights that North America holds the largest regional share while Asia-Pacific is the fastest-growing region, with software and on-premises delivery modes currently dominating the landscape. Key industry developments include AllazoHealth's launch of AI software for medication adherence and a strategic integration between SEQSTER and PatientsLikeMe.AssistrxAllazoHealth, an AssistRx SolutionAllazoHealth, an AssistRx Solution, is an AI-driven patient engagement platform designed to improve therapy initiation and adherence through personalized outreach. The solution utilizes predictive intelligence trained on over 29 million patient journeys to optimize program performance and reduce operational costs for life sciences organizations.GlobeNewswireAssistRx Completes Asset Acquisition from AllazoHealth, Strengthening its Advanced Tech + Talent Patient Support ServicesAssistRx completed an asset acquisition from AllazoHealth, adding AI-powered patient engagement technology to its portfolio. The acquisition strengthens AssistRx's advanced therapy initiation and patient support services, aiming to improve patient adherence and outcomes. The integration aligns with AssistRx's vision of combining technology and therapy expertise.The Manila TimesAssistRx Completes Asset Acquisition from AllazoHealth, Strengthening its Advanced Tech + Talent Patient Support ServicesAssistRx completed an asset acquisition from AllazoHealth, adding AI-powered patient engagement technology to its portfolio. The integration aims to enhance therapy initiation, adherence, and health outcomes for life sciences clients. AssistRx's co-founder Edward Hensley cited the acquisition as a continued investment in advanced solutions.Business Wire BlogTop 10 Rare Diseases Pharma Company Sees 10.4% Increase in Therapy Initiation with AllazoHealth AI-Enabled Personalized CommunicationsAllazoHealth released a case study showing a top 10 rare diseases pharma company's AI-enabled personalization increased therapy initiation by 10.4% and decreased discontinuation by 7.3%. The solution personalized communications for about 10,000 patients, reducing nurse outreach calls. The company reported positive qualitative results and exceeded initial goals.Business Wire BlogAllazoHealth Unveils Next-Generation AI-Enabled Content Optimization Solution to Help Pharmaceutical Companies Personalize Patient Communications, Improve Medication Initiation and AdherenceAllazoHealth announced its AI-Enabled Dynamic Modular Content, which personalizes patient communications to improve medication initiation and adherence. The solution uses AI to predict individual patient behaviors and tailor content, with a top 20 pharmaceutical company seeing patients stay on therapy 12.2% longer. It is HIPAA compliant and integrates with major marketing platforms.GlobeNewswireAllazoHealth Partners with Top 10 Rare Diseases Company to Enhance Patient Support ProgramsAllazoHealth is partnering with a top 10 rare disease company to expand into rare disease patient support, launching an Impact Calculator to demonstrate AI-driven effectiveness. The company cites case study results including 5.5x greater adherence uplift and 13.3% increase in days on therapy. The partnership aims to address the challenge of small patient populations in rare disease treatments.PrwebAllazoHealth names pharmaceutical industry analytics expert Mark Degatano to advisory boardAllazoHealth appointed pharmaceutical industry analytics expert Mark Degatano to its advisory board. Degatano brings over 35 years of experience, including 24 years at Merck as VP of Customer Insights. He will join immediately, citing AllazoHealth's AI approach to patient engagement.PR NewswireAI Analysis Shows COVID-19 Widens Disparity in Medication Adherence Between Patient PopulationsAllazoHealth, a healthcare technology company, released an analysis on April 2, 2020, showing that the COVID-19 pandemic has widened the gap in medication adherence between high-risk and low-risk patient populations in the United States. The data reveals that the gap between high-risk and low-risk patients who fill their prescriptions late increased from 14% pre-COVID-19 to 20% post-COVID-19. The company recommends that health plans and pharmacies engage with high-risk patients through interventions such as home delivery services or longer prescription supplies to address the disparity.